Theravance Biopharma (NASDAQ: TBPH) announced enrollment of the first patient in the Company's Telavancin Observational Use Registry (TOUR). The study ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE